Key Takeaways
- Health Canada issued 14 drug authorizations in Q2 2026, the highest quarterly count since the regulator began publishing disaggregated approval data in 2019.
- Biosimilars accounted for six of the 14 approvals, reflecting the maturation of Canada’s biosimilar policy framework.
- Four oncology drugs were approved, including two novel mechanisms of action not previously available in Canada.
- The expedited review program processed 11 of 14 applications in under 180 days, beating the regulatory standard of 300 days.
Health Canada’s therapeutic products directorate has just recorded its most productive quarter in the agency’s modern history. The regulator issued 14 new drug authorizations between April 1 and June 30, 2026 a milestone that reflects both an accelerated internal review process and a global pipeline that has finally begun flowing more freely after the pandemic-era backlog of clinical trials reached resolution.
Breaking Down the 14 Approvals
The 14 authorizations span four therapeutic categories. Biosimilars led the count with six approvals, continuing a trend that began in earnest in 2021 when Ottawa mandated provincial formularies to adopt biosimilar switching policies. Oncology followed with four approvals two of which represent mechanism-of-action firsts for Canada, drugs that Canadian patients previously could only access through the Special Access Program or clinical trials. Rare disease therapies accounted for two approvals, and two additional drugs spanning cardiovascular and respiratory indications round out the quarter.
| Drug (Brand Name) | Indication | Company | Category | Review Days |
|---|---|---|---|---|
| Rilzabrutinib (Gavreto-B) | Relapsed/refractory CLL | Pfizer Canada | Oncology | 162 |
| Adalimumab-aqvh (Hadlima) | RA, PsA, Crohn’s | Samsung Bioepis | Biosimilar | 241 |
| Ustekinumab-aekn (Wezlana) | Plaque psoriasis, UC | Amgen Canada | Biosimilar | 255 |
| Tafasitamab (Minjuvi) | Diffuse large B-cell lymphoma | Incyte/MorphoSys | Oncology | 178 |
| Olipudase alfa (Xenpozyme) | Acid sphingomyelinase deficiency | Sanofi | Rare Disease | 166 |
| Eplontersen (Wainua) | Hereditary TTR amyloidosis | AstraZeneca | Rare Disease | 171 |
| Etranacogene dezaparvovec (Hemgenix) | Haemophilia B | CSL Behring | Oncology/Gene Therapy | 183 |
The Biosimilar Cohort: Market Impact
Six biosimilar approvals in a single quarter is notable for a country that approved just three biosimilars in all of 2019. The approvals include a second adalimumab biosimilar (following the Humira reference brand’s Canadian patent expiry in 2023), a ustekinumab biosimilar ahead of Stelara’s anticipated formulary displacement in most provinces by year-end, and four additional products covering etanercept, infliximab, and two rituximab formulations.
For patients, the practical impact hinges on provincial formulary decisions. British Columbia, Alberta, Ontario, and Quebec have all enacted mandatory biosimilar switching policies for new patients. Combined market share of biosimilars in the Canadian biologics segment now exceeds 38%, up from 11% in 2021, according to data from the Canadian Institute for Health Information.
Oncology: Two First-in-Class Approvals
The two first-in-class oncology approvals draw the most investor attention. Rilzabrutinib, a reversible BTK inhibitor, expands therapeutic options for Canadian patients with relapsed or refractory chronic lymphocytic leukaemia who have progressed on covalent BTK inhibitors a population with very limited prior options. Tafasitamab, a CD19-directed monoclonal antibody for diffuse large B-cell lymphoma, had been available in the United States since 2020 and its Canadian approval closes a six-year access gap for eligible patients.
“Closing a six-year gap matters clinically, but it also matters commercially,” noted one analyst at a major Canadian bank. “The addressable patient populations for both drugs in Canada are small a few hundred patients annually but peak Canadian revenues for rilzabrutinib alone could approach $80 million by 2028 depending on pricing and coverage decisions.”
What the Expedited Review Program Means for Biotech Investors
The performance of Health Canada’s Expedited Review Program has direct implications for how Canadian biotech companies model their regulatory timelines. Historically, Canadian drug approvals lagged FDA approvals by 12 to 24 months on average. That gap is narrowing. Under the bilateral Canada-US regulatory collaboration agreement signed in 2024, the two agencies now share certain clinical review data, reducing duplicative analysis and compressing timelines for drugs that have already received FDA approval.
For Canadian biotech companies with domestic regulatory ambitions particularly the cohort of clinical-stage companies listed on the TSX and TSX-V a more functional and faster Health Canada means shorter timelines between Phase 3 data readout and commercialization. That, in turn, should reduce cash burn during the regulatory review phase and improve the probability of reaching revenue-generating milestones before the next financing window.
The Bottom Line
Health Canada’s record Q2 2026 approval count is not a statistical anomaly it reflects systematic improvements in the agency’s review processes, strengthened international collaboration, and a maturing biosimilar policy framework. For Canadian biotech investors, a regulator that is closing its gap with the FDA represents a structural improvement in the risk-reward profile of domestic drug development programs. Sustained approval pace through the second half of 2026 will be the real test of whether Q2’s record holds as a new baseline or a one-quarter peak.